MBX Biosciences, Inc. (MBX)
NASDAQ:MBX
Want to see MBX full AI Analyst Report?
Top Page
MBX Biosciences, Inc.
(NASDAQ:MBX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$41.00
▲(21.41% Upside)
Action:Reiterated
Date:06/12/26
The score is held back mainly by weak financial performance (no revenue, widening losses, and worsening cash burn) and a valuation profile dominated by losses (negative P/E, no dividend). These are partially offset by supportive technical trend positioning (price above key moving averages) and meaningful positive pipeline-driven corporate events (strong Phase 2 results and planned Phase 3 progression).
Positive Factors
Clinical progression: strong Phase 2 canvuparatide results
Robust Phase 2 and one-year open-label results plus a planned Phase 3 start represent a durable de-risking step for the lead program. Successful pivotal progression can enable regulatory submission, commercialization or partnering, shifting the company from discovery to potential revenue generation.
Negative Factors
Pre-revenue with materially widening net losses
A sustained pre-revenue profile with rapidly expanding losses means value creation depends wholly on clinical success. This durable constraint increases dependency on external capital and partners, prolongs time to profitability, and raises execution risk versus commercial-stage peers.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical progression: strong Phase 2 canvuparatide results
Robust Phase 2 and one-year open-label results plus a planned Phase 3 start represent a durable de-risking step for the lead program. Successful pivotal progression can enable regulatory submission, commercialization or partnering, shifting the company from discovery to potential revenue generation.
Read all positive factors
MBX Biosciences, Inc. (MBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.05B
Dividend YieldN/A
Average Volume (3M)874.16K
Price to Earnings (P/E)―
Beta (1Y)2.13
Revenue GrowthN/A
EPS Growth-0.43%
CountryUS
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.20
Shares Outstanding47,597,534
10 Day Avg. Volume1,112,847
30 Day Avg. Volume874,156
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)3.12
Price to Sales (P/S)0.00
P/FCF Ratio-14.06
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.04K
Enterprise Value/Ebitda-15.66
Forecast
1Y Price Target
$74.75Price Target Upside121.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.81
Revenue Forecast (FY)N/A
MBX Biosciences, Inc. Business Overview & Revenue Model
Company Description
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid ho...
How the Company Makes Money
null...
MBX Biosciences, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -224.00K | -248.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -86.37M | -86.72M | -61.68M | -32.41M | -25.70M |
| Net Income | -86.61M | -86.97M | -61.92M | -32.56M | -26.14M |
Balance Sheet | |||||
| Total Assets | 452.70M | 385.14M | 268.54M | 84.18M | 45.09M |
| Cash, Cash Equivalents and Short-Term Investments | 439.98M | 373.70M | 262.15M | 80.68M | 42.46M |
| Total Debt | 555.00K | 596.00K | 171.00K | 324.00K | 461.00K |
| Total Liabilities | 14.95M | 15.92M | 11.09M | 156.65M | 87.70M |
| Stockholders Equity | 437.76M | 369.22M | 257.44M | -72.47M | -42.60M |
Cash Flow | |||||
| Free Cash Flow | -79.81M | -81.88M | -55.55M | -32.11M | -23.56M |
| Operating Cash Flow | -77.48M | -79.95M | -54.68M | -31.98M | -23.12M |
| Investing Cash Flow | -184.03M | -83.70M | -160.59M | -30.93M | -11.41M |
| Financing Cash Flow | 277.02M | 189.59M | 234.10M | 69.22M | 46.06M |
MBX Biosciences, Inc. Risk Analysis
MBX Biosciences, Inc. disclosed 93 risk factors in its most recent earnings report. MBX Biosciences, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MBX Biosciences, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $1.81B | -6.54 | -64.21% | ― | 27.23% | -12.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.68B | -13.34 | -42.66% | ― | ― | -33.07% | |
49 Neutral | $2.05B | -23.14 | -24.50% | ― | ― | -0.43% | |
44 Neutral | $82.13M | -0.22 | 174.85% | ― | -55.42% | -248.85% |
* Healthcare Sector Average
MBX
MBX Biosciences, Inc.
43.03
33.29
341.79%
GOSS
Gossamer Bio
0.17
-1.27
-88.33%
NRIX
Nurix Therapeutics
17.55
6.06
52.74%
TYRA
Tyra Bioscience
28.32
19.09
206.83%
MBX Biosciences, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
MBX Biosciences unveils positive Phase 2 canvuparatide results
Positive
Jun 12, 2026
On June 12, 2026, MBX Biosciences reported full 12-week Phase 2 Avail data and one-year open-label extension results for once-weekly canvuparatide in adults with chronic hypoparathyroidism. The therapy achieved a 63% responder rate versus 31% for ...
Executive/Board ChangesShareholder Meetings
MBX Biosciences Shareholders Approve Directors and Auditor
Positive
Jun 5, 2026
MBX Biosciences, Inc., a publicly traded biopharmaceutical company with 47,570,485 outstanding common shares as of April 10, 2026, held its 2026 annual meeting of stockholders on June 4, 2026. Shareholders considered board elections and the select...
Business Operations and StrategyProduct-Related Announcements
MBX Biosciences Highlights Positive Phase 1 Obesity Data
Positive
May 11, 2026
On May 11, 2026, MBX Biosciences reported preliminary blinded Phase 1 data for its dual GLP-1/GIP prodrug MBX 4291 in adults with obesity, showing dose-proportional pharmacokinetics, a slow-release profile compatible with once-monthly dosing, and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.